By harnessing light, my colleagues and I designed a wireless, ultrathin pacemaker that operates like a solar panel. This design not only eliminates the need for batteries but also minimizes disruptions to the heart’s natural function by molding to its contours. Our research, recently published in the journal Nature, offers a new approach to treatments that require electrical stimulation, such as heart pacing.
Pacemakers are medical devices implanted in the body to regulate heart rhythms. They’re composed of electronic circuits with batteries and leads anchored to the heart muscle to stimulate it. However, leads can fail and damage tissue. The location of the leads can’t be changed once they’re implanted, limiting access to different heart regions. Because pacemakers use rigid, metallic electrodes, they may also damage tissue when restarting the heart after surgery or regulating arrhythmia.
Our team envisioned a leadless and more flexible pacemaker that could precisely stimulate multiple areas of the heart. So we designed a device that transforms light into bioelectricity, or heart cell-generated electrical signals. Thinner than a human hair, our pacemaker is made of an optic fiber and silicon membrane that the Tian lab and colleagues at the University of Chicago Pritzker School of Molecular Engineering have spent years developing.
Like solar panels, this pacemaker is powered by light.
Unlike conventional solar cells that are usually designed to collect as much energy as possible, we tweaked our device to generate electricity only at points where light strikes so it can precisely regulate heartbeats. We did this by using a layer of very small pores that can trap light and electrical current. Only cardiac muscles exposed to light-activated pores are stimulated.
Because our device is so small and light, it can be implanted without opening the chest. We were able to successfully implant it in the hearts of rodents and an adult pig, pacing the beats of different heart muscles. Because pig hearts are anatomically similar to human hearts, this accomplishment shows our device’s potential to translate to people.
Why it matters
Heart disease is the leading cause of death around the world. Annually, over 2 million people undergo open-heart surgery to treat heart problems, including to implant devices that regulate heart rhythms and prevent heart attacks.
Our ultralight device gently conforms to the surface of the heart, enabling less invasive stimulation and improved pacing and synchronized contraction. To reduce postoperative trauma and recovery time, our device can be implanted with a minimally invasive technique.
What still isn’t known
Currently, our technology is best first used for urgent heart conditions, including restarting the heart after surgery, heart attack and ventricular defibrillation. We continue to explore its long-term effects and durability in the human body.
The body’s internal environment is rich in fluids that are disturbed by the heart’s constant mechanical motion. This could potentially compromise the device’s functionality over time.
Pacemaker syndrome is a condition that develops from stimulating heart muscles in isolation. Michael Rosengarten BEng, MD.McGill/EKG World Encyclopedia via Wikimedia Commons, CC BY-SA
Moreover, researchers don’t fully understand how the body reacts to prolonged exposure to medical devices. The formation of scar tissue around the device after implantation can diminish its sensitivity. We are developing special surface treatments and biomaterial coatings to decrease the likelihood of rejection.
Although the breakdown of our device results in a nontoxic substance the body can safely absorb called silicic acid, evaluating how the body responds to extended implantation is essential to ensure safety and effectiveness.
What’s next
To achieve long-term implantation and tailor the device to each patient, we are refining the rate at which it dissolves naturally in the body. We are exploring enhancements to make the device compatible as a wearable pacemaker. This involves integrating a wireless light-emitting diode, or LED, beneath the skin that is connected to the device via an optical fiber.
Our ultimate goal is to broaden the scope of what we call photoelectroceuticals beyond cardiac care. This includes neurostimulation, neuroprostheses and pain management to treat neurodegenerative conditions such as Parkinson’s disease.


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 




